SWM
ANIK icon

Spire Wealth Management’s Anika Therapeutics ANIK Stock Holding History

Spire Wealth Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-213
Closed -$2K – 2304
2025
Q3 		$2K Sell
213
-84
-28% -$802 ﹤0.01% 2166
2025
Q2 		$3.14K Sell
297
-214
-42% -$2.7K ﹤0.01% 2071
2025
Q1 		$7.68K Buy
+511
New +$8.5K ﹤0.01% 1923
2021
Q2 		– Sell
-447
Closed -$16K – 2578
2021
Q1 		$16K Buy
+447
New +$17K ﹤0.01% 2231

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Spire Wealth Management's ANIK Position: Q4 2025 in Review

Spire Wealth Management sold out of Anika Therapeutics (ANIK) in Q4 2025, closing a stake of 213 shares — an estimated $2K sold.

Spire Wealth Management first reported a position in ANIK in Q1 2021 and held it in 4 quarters. The position peaked at $16K in Q1 2021. 126 funds tracked by Wall St. Rank hold ANIK as of Q4 2025.

  • Spire Wealth Management reported no remaining Anika Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Spire Wealth Management sold 213 Anika Therapeutics shares in Q4 2025, an estimated $2K.
  • Spire Wealth Management first reported a position in Anika Therapeutics in Q1 2021 and held it in 4 quarters.
  • Spire Wealth Management's Anika Therapeutics position peaked at $16K in Q1 2021.
  • 126 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2025.

Based on Spire Wealth Management's 13F filing for Q4 2025, filed 14 Jan 2026.